Effects of Isradipine, A New Calcium Antagonist, on Postpartum Uterine Activity

I. Ingemarsson, S. Arulkumaran, D. Wide‐Swensson, A. Forman, K. ‐E Andersson, S. S. Ratnam

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effects of a new calcium antagonist, isradipine (PN 200–110) on postpartum uterine activity and the maternal cardiovascular system were investigated. Uterine activity was recorded by a microtip transducer catheter inserted transcer‐vically within 45 min of normal vaginal delivery. 0.5 mg of isradipine was given as a bolus injection during 5 min to 7 women with spontaneous uterine activity and 1 mg was given during a 15‐min period to another 8 women with oxytocin‐stimulated uterine activity. Matched controls with similar pre‐injection activity (±5%) but not given the drug were selected for comparison. The effects of the drug in 3 women (given 1 mg of isradipine) were compared with those in matched controls and in women given 0.25 mg of terbutalin i.v. as a bolus injection. lsradipine had a marked inhibitory effect on both spontaneous and oxytocin‐stimulated uterine activity. The inhibitory effect of 1 mg of isradipine seemed comparable to that of 0.25 mg of terbutalin. The inhibition occurred within 1–2 min after the injection and was sustained throughout the study period (2 h). A transient reduction of the systolic (mean maximum decrease 10–15%) and diastolic blood pressure (mean maximum decrease 15–2096) was seen, particularly during the injection period. Hypotension (systolic blood pressure < 80 mmHg) was not recorded. A moderate increase in pulse rate (mean maximum increase 22–27%) was seen in all cases. The results show that isradipine given as a bolus injection can inhibit early postpartum uterine activity, with minimal side effects. 1989 Acta Obstet Gynecol Scand

Original languageEnglish
Pages (from-to)725-730
Number of pages6
JournalActa Obstetricia et Gynecologica Scandinavica
Volume68
Issue number8
DOIs
Publication statusPublished - 1989

Fingerprint

Isradipine
Postpartum Period
Calcium
Injections
Blood Pressure
Cardiovascular System
Transducers
Pharmaceutical Preparations
Hypotension
Catheters
Heart Rate
Mothers

Cite this

Ingemarsson, I. ; Arulkumaran, S. ; Wide‐Swensson, D. ; Forman, A. ; Andersson, K. ‐E ; Ratnam, S. S. / Effects of Isradipine, A New Calcium Antagonist, on Postpartum Uterine Activity. In: Acta Obstetricia et Gynecologica Scandinavica. 1989 ; Vol. 68, No. 8. pp. 725-730.
@article{728ce5bdeb9b4ecb98adf59f0f1b7a82,
title = "Effects of Isradipine, A New Calcium Antagonist, on Postpartum Uterine Activity",
abstract = "The effects of a new calcium antagonist, isradipine (PN 200–110) on postpartum uterine activity and the maternal cardiovascular system were investigated. Uterine activity was recorded by a microtip transducer catheter inserted transcer‐vically within 45 min of normal vaginal delivery. 0.5 mg of isradipine was given as a bolus injection during 5 min to 7 women with spontaneous uterine activity and 1 mg was given during a 15‐min period to another 8 women with oxytocin‐stimulated uterine activity. Matched controls with similar pre‐injection activity (±5{\%}) but not given the drug were selected for comparison. The effects of the drug in 3 women (given 1 mg of isradipine) were compared with those in matched controls and in women given 0.25 mg of terbutalin i.v. as a bolus injection. lsradipine had a marked inhibitory effect on both spontaneous and oxytocin‐stimulated uterine activity. The inhibitory effect of 1 mg of isradipine seemed comparable to that of 0.25 mg of terbutalin. The inhibition occurred within 1–2 min after the injection and was sustained throughout the study period (2 h). A transient reduction of the systolic (mean maximum decrease 10–15{\%}) and diastolic blood pressure (mean maximum decrease 15–2096) was seen, particularly during the injection period. Hypotension (systolic blood pressure < 80 mmHg) was not recorded. A moderate increase in pulse rate (mean maximum increase 22–27{\%}) was seen in all cases. The results show that isradipine given as a bolus injection can inhibit early postpartum uterine activity, with minimal side effects. 1989 Acta Obstet Gynecol Scand",
author = "I. Ingemarsson and S. Arulkumaran and D. Wide‐Swensson and A. Forman and Andersson, {K. ‐E} and Ratnam, {S. S.}",
year = "1989",
doi = "10.3109/00016348909006146",
language = "English",
volume = "68",
pages = "725--730",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "8",

}

Effects of Isradipine, A New Calcium Antagonist, on Postpartum Uterine Activity. / Ingemarsson, I.; Arulkumaran, S.; Wide‐Swensson, D.; Forman, A.; Andersson, K. ‐E; Ratnam, S. S.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 68, No. 8, 1989, p. 725-730.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of Isradipine, A New Calcium Antagonist, on Postpartum Uterine Activity

AU - Ingemarsson, I.

AU - Arulkumaran, S.

AU - Wide‐Swensson, D.

AU - Forman, A.

AU - Andersson, K. ‐E

AU - Ratnam, S. S.

PY - 1989

Y1 - 1989

N2 - The effects of a new calcium antagonist, isradipine (PN 200–110) on postpartum uterine activity and the maternal cardiovascular system were investigated. Uterine activity was recorded by a microtip transducer catheter inserted transcer‐vically within 45 min of normal vaginal delivery. 0.5 mg of isradipine was given as a bolus injection during 5 min to 7 women with spontaneous uterine activity and 1 mg was given during a 15‐min period to another 8 women with oxytocin‐stimulated uterine activity. Matched controls with similar pre‐injection activity (±5%) but not given the drug were selected for comparison. The effects of the drug in 3 women (given 1 mg of isradipine) were compared with those in matched controls and in women given 0.25 mg of terbutalin i.v. as a bolus injection. lsradipine had a marked inhibitory effect on both spontaneous and oxytocin‐stimulated uterine activity. The inhibitory effect of 1 mg of isradipine seemed comparable to that of 0.25 mg of terbutalin. The inhibition occurred within 1–2 min after the injection and was sustained throughout the study period (2 h). A transient reduction of the systolic (mean maximum decrease 10–15%) and diastolic blood pressure (mean maximum decrease 15–2096) was seen, particularly during the injection period. Hypotension (systolic blood pressure < 80 mmHg) was not recorded. A moderate increase in pulse rate (mean maximum increase 22–27%) was seen in all cases. The results show that isradipine given as a bolus injection can inhibit early postpartum uterine activity, with minimal side effects. 1989 Acta Obstet Gynecol Scand

AB - The effects of a new calcium antagonist, isradipine (PN 200–110) on postpartum uterine activity and the maternal cardiovascular system were investigated. Uterine activity was recorded by a microtip transducer catheter inserted transcer‐vically within 45 min of normal vaginal delivery. 0.5 mg of isradipine was given as a bolus injection during 5 min to 7 women with spontaneous uterine activity and 1 mg was given during a 15‐min period to another 8 women with oxytocin‐stimulated uterine activity. Matched controls with similar pre‐injection activity (±5%) but not given the drug were selected for comparison. The effects of the drug in 3 women (given 1 mg of isradipine) were compared with those in matched controls and in women given 0.25 mg of terbutalin i.v. as a bolus injection. lsradipine had a marked inhibitory effect on both spontaneous and oxytocin‐stimulated uterine activity. The inhibitory effect of 1 mg of isradipine seemed comparable to that of 0.25 mg of terbutalin. The inhibition occurred within 1–2 min after the injection and was sustained throughout the study period (2 h). A transient reduction of the systolic (mean maximum decrease 10–15%) and diastolic blood pressure (mean maximum decrease 15–2096) was seen, particularly during the injection period. Hypotension (systolic blood pressure < 80 mmHg) was not recorded. A moderate increase in pulse rate (mean maximum increase 22–27%) was seen in all cases. The results show that isradipine given as a bolus injection can inhibit early postpartum uterine activity, with minimal side effects. 1989 Acta Obstet Gynecol Scand

UR - http://www.scopus.com/inward/record.url?scp=0024936279&partnerID=8YFLogxK

U2 - 10.3109/00016348909006146

DO - 10.3109/00016348909006146

M3 - Article

C2 - 2534341

AN - SCOPUS:0024936279

VL - 68

SP - 725

EP - 730

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 8

ER -